Population based screening for chronic kidney disease: cost effectiveness study

被引:111
作者
Manns, Braden [1 ,2 ,3 ]
Hemmelgarn, Brenda [1 ,2 ,3 ]
Tonelli, Marcello [3 ,4 ]
Au, Flora [3 ]
Chiasson, T. Carter [3 ]
Dong, James [3 ,4 ]
Klarenbach, Scott [3 ,4 ]
机构
[1] Univ Calgary, Dept Med, Calgary, AB, Canada
[2] Univ Calgary, Libin Cardiovasc Inst Alberta, Calgary, AB, Canada
[3] Alberta Kidney Dis Network, Calgary, AB, Canada
[4] Univ Alberta, Dept Med, Div Nephrol, Edmonton, AB, Canada
来源
BMJ-BRITISH MEDICAL JOURNAL | 2010年 / 341卷
关键词
CONVERTING ENZYME-INHIBITORS; EARLY EVALUATION PROGRAM; QUALITY-OF-LIFE; NONDIABETIC RENAL-DISEASE; CARDIOVASCULAR EVENTS; ECONOMIC-EVALUATION; BLOOD-PRESSURE; RISK-FACTORS; HEALTH; PROGRESSION;
D O I
10.1136/bmj.c5869
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To determine the cost effectiveness of one-off population based screening for chronic kidney disease based on estimated glomerular filtration rate. Design Cost utility analysis of screening with estimated glomerular filtration rate alone compared with no screening (with allowance for incidental finding of cases of chronic kidney disease). Analyses were stratified by age, diabetes, and the presence or absence of proteinuria. Scenario and sensitivity analyses, including probabilistic sensitivity analysis, were performed. Costs were estimated in all adults and in subgroups defined by age, diabetes, and hypertension. Setting Publicly funded Canadian healthcare system. Participants Large population based laboratory cohort used to estimate mortality rates and incidence of end stage renal disease for patients with chronic kidney disease over a five year follow-up period. Patients had not previously undergone assessment of glomerular filtration rate. Main outcome measures Lifetime costs, end stage renal disease, quality adjusted life years (QALYs) gained, and incremental cost per QALY gained. Results Compared with no screening, population based screening for chronic kidney disease was associated with an incremental cost of $C463 (Canadian dollars in 2009; equivalent to about 275 pound, (sic)308, US $382) and a gain of 0.0044 QALYs per patient overall, representing a cost per QALY gained of $C104 900. In a cohort of 100 000 people, screening for chronic kidney disease would be expected to reduce the number of people who develop end stage renal disease over their lifetime from 675 to 657. In subgroups of people with and without diabetes, the cost per QALY gained was $C22 600 and $C572 000, respectively. In a cohort of 100 000 people with diabetes, screening would be expected to reduce the number of people who develop end stage renal disease over their lifetime from 1796 to 1741. In people without diabetes with and without hypertension, the cost per QALY gained was $C334 000 and $C1 411 100, respectively. Conclusions Population based screening for chronic kidney disease with assessment of estimated glomerular filtration rate is not cost effective overall or in subgroups of people with hypertension or older people. Targeted screening of people with diabetes is associated with a cost per QALY that is similar to that accepted in other interventions funded by public healthcare systems.
引用
收藏
页数:12
相关论文
共 72 条
[21]   Albuminuria and renal insufficiency prevalence guides population screening: Results from the NHANES III [J].
Garg, AX ;
Kiberd, BA ;
Clark, WF ;
Haynes, RB ;
Clase, CM .
KIDNEY INTERNATIONAL, 2002, 61 (06) :2165-2175
[22]  
Gerstein HC, 2000, LANCET, V355, P253
[23]   Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials [J].
Giatras, I ;
Lau, J ;
Levey, AS .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (05) :337-+
[24]   Health-related quality of life and estimates of utility in chronic kidney disease [J].
Gorodetskaya, I ;
Zenios, S ;
McCulloch, CE ;
Bostrom, A ;
Hsu, CY ;
Bindman, AB ;
Go, AS ;
Chertow, GM .
KIDNEY INTERNATIONAL, 2005, 68 (06) :2801-2808
[25]   Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey [J].
Hallan, Stein I. ;
Dahl, Ketil ;
Oien, Cecilia M. ;
Grootendorst, Diana C. ;
Aasberg, Arne ;
Holmen, Jostein ;
Dekker, Friedo W. .
BMJ-BRITISH MEDICAL JOURNAL, 2006, 333 (7577) :1047-1050
[26]   Association between multidisciplinary care and survival for elderly patients with chronic kidney disease [J].
Hemmelgarn, Brenda R. ;
Manns, Braden J. ;
Zhang, Jianguo ;
Tonelli, Marcello ;
Klarenbach, Scott ;
Walsh, Michael ;
Culleton, Bruce F. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (03) :993-999
[27]   Overview of the Alberta Kidney Disease Network [J].
Hemmelgarn, Brenda R. ;
Clement, Fiona ;
Manns, Braden J. ;
Klarenbach, Scott ;
James, Matthew T. ;
Ravani, Pietro ;
Pannu, Neesh ;
Ahmed, Sofia B. ;
MacRae, Jennifer ;
Scott-Douglas, Nairne ;
Jindal, Kailash ;
Quinn, Robert ;
Culleton, Bruce F. ;
Wiebe, Natasha ;
Krause, Richard ;
Thorlacius, Laurel ;
Tonelli, Marcello .
BMC NEPHROLOGY, 2009, 10
[28]   Relation Between Kidney Function, Proteinuria, and Adverse Outcomes [J].
Hemmelgarn, Brenda R. ;
Manns, Braden J. ;
Lloyd, Anita ;
James, Matthew T. ;
Klarenbach, Scott ;
Quinn, Robert R. ;
Wiebe, Natasha ;
Tonelli, Marcello .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (05) :423-429
[29]   Diabetes in Ontario - Determination of prevalence and incidence using a validated administrative data algorithm [J].
Hux, JE ;
Flintoft, V ;
Ivis, F ;
Bica, A .
DIABETES CARE, 2002, 25 (03) :512-516
[30]   Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease - A meta-analysis of patient-level data [J].
Jafar, TH ;
Schmid, CH ;
Landa, M ;
Giatras, I ;
Toto, R ;
Remuzzi, G ;
Maschio, G ;
Brenner, BM ;
Kamper, A ;
Zucchelli, P ;
Becker, G ;
Himmelmann, A ;
Bannister, K ;
Landais, P ;
Shahinfar, S ;
de Jong, PE ;
de Zeeuw, D ;
Lau, J ;
Levey, AS .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (02) :73-87